<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151408</url>
  </required_header>
  <id_info>
    <org_study_id>PRAN-16-52</org_study_id>
    <nct_id>NCT03151408</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo&#xD;
      with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly&#xD;
      diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic leukemia and&#xD;
      cytogenetic low-risk AML, who are unfit to receive intensive remission induction chemotherapy&#xD;
      due to age ≥ 75 years or comorbidities. Patients will be randomized in a 1:1 ratio to one of&#xD;
      two groups: Group A (experimental group) to receive pracinostat plus AZA and Group B (control&#xD;
      group) to receive placebo plus AZA. Randomization will be stratified by cytogenetic risk&#xD;
      category (intermediate vs. unfavorable-risk, according to SWOG Cytogenetic Risk Category&#xD;
      Definitions) and ECOG performance status (0-1 vs. 2). Treatments will be administered based&#xD;
      on 28-day cycles, with pracinostat/placebo administered orally once every other day, 3 times&#xD;
      a week for 3 weeks, followed by one week of no treatment and AZA administered for 7 days of&#xD;
      each cycle. Study treatment should continue until there is documented disease progression,&#xD;
      relapse from complete remission (CR), or non-manageable toxicity. A minimum of 6 cycles may&#xD;
      be required to achieve a complete remission. Once permanently discontinued from study&#xD;
      treatment, patients will enter the Long-term Follow-up phase of the study and will be&#xD;
      followed for assessment of disease progression, if applicable, and survival every 3 months&#xD;
      (±1 month) until death. The end of this study is defined when 390 events (deaths) have&#xD;
      occurred and the study is unblinded for final overall survival analysis. Patients who are&#xD;
      receiving study treatment at the end of the study may have the opportunity to continue to&#xD;
      receive the study drugs to which they were randomized to (Post- Study Observation Period),&#xD;
      until the Sponsor informs the Investigators of the appropriate course of action based on the&#xD;
      study results. The Post-Study Observation Period is defined as the period starting from the&#xD;
      end of the study for a maximum of 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The IDMC recommended to stop the study prematurely due to a lack of efficacy.&#xD;
  </why_stopped>
  <start_date type="Actual">June 23, 2017</start_date>
  <completion_date type="Actual">August 20, 2020</completion_date>
  <primary_completion_date type="Actual">August 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate efficacy rate</measure>
    <time_frame>1 year</time_frame>
    <description>To show superiority in terms of overall survival (OS) of treatment with pracinostat (Group A - experimental group) versus placebo (Group B - control group) in patients treated with AZA as background therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphologic Complete Remission (CR) rate</measure>
    <time_frame>1 year</time_frame>
    <description>The CR rate is the proportion of patients who achieve a morphologic CR according to the response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission without minimal residual disease (CRmrd) rate</measure>
    <time_frame>1 year</time_frame>
    <description>proportion of patients who achieve a CR without minimal residual disease by multi colr flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic Complete Remission (CRc) rate</measure>
    <time_frame>1 year</time_frame>
    <description>The CRc rate is the proportion of patients who achieve a reversion to a normal karyotype at CR within the study period. This endpoint applies only to patients with abnormal cytogenetic at enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion Independence (TI)</measure>
    <time_frame>1 year</time_frame>
    <description>Transfusion independence rate is defined as the proportion of patients who show eight weeks or over without red blood cell (RBC-TI) and/or platelet (PLT-TI) transfusion during study period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite Complete Remission (cCR) rate</measure>
    <time_frame>1 year</time_frame>
    <description>Composite complete remission (cCR) rate is the proportion of patients who achieve either a disease response of CR, CRi or MLFS (i.e., cCR = CR + CRi + MLFS) within the study period, according to the response criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Composite Complete Remission</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of cCR response is the time from first cCR until documented relapse (the definition of relapse from CR will be applied) or death. Duration of cCR is only defined for patients who achieve a cCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Cytogenetic Complete Remission</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of cytogenetic complete remission is the time from first CRc until documented relapse (defined as reappearance of abnormal karyotype or relapse from CR) or death. Duration of CRc is only defined for patients who achieve a CRc</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life: EORTC QLQ-C30</measure>
    <time_frame>1 year</time_frame>
    <description>Computation of the global health status and of selected functional scales and symptom scales from the EORTC QLQ-C30 questionnaire will be performed and their change from baseline over the study period will constitute the endpoints.</description>
  </other_outcome>
  <other_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>1 year</time_frame>
    <description>the time from the date of achievement of CR or CRi until the date of relapse or death from any cause</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Pracinostat plus AZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus AZA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pracinostat</intervention_name>
    <description>60 mg capsule</description>
    <arm_group_label>Pracinostat plus AZA</arm_group_label>
    <other_name>SB939</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>capsule</description>
    <arm_group_label>Placebo plus AZA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>SC or IV injection</description>
    <arm_group_label>Placebo plus AZA</arm_group_label>
    <arm_group_label>Pracinostat plus AZA</arm_group_label>
    <other_name>AZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient ≥ 18 years of age with newly diagnosed, histologically or&#xD;
             cytologically confirmed, AML including de novo, secondary to antecedent hematologic&#xD;
             disorders, or treatment-related disease with intermediate or unfavorable-risk&#xD;
             cytogenetics&#xD;
&#xD;
          2. Unable to receive intensive chemotherapy regimens at enrollment, based on one of the&#xD;
             following:&#xD;
&#xD;
             I. Age ≥ 75 years, or&#xD;
&#xD;
             II. Age &lt; 75 years with at least 1 of the following co-morbidities:&#xD;
&#xD;
               1. An ECOG performance status of 2&#xD;
&#xD;
               2. Clinically significant cardiovascular disease defined as:&#xD;
&#xD;
             i. Left ventricular ejection fraction (LVEF) ≤ 50%, measured within 3 months prior to&#xD;
             Day 1 confirmed by ECHO/MUGA ii. Congestive heart failure requiring medical therapy&#xD;
             iii. Chronic stable angina requiring medical therapy iv. Prior cerebrovascular&#xD;
             accident with sequelae c. Clinically significant pulmonary disease defined as: i.&#xD;
             Forced expiratory volume in 1 second (FEV1) ≤ 65% of expected ii. Lung diffusing&#xD;
             capacity for carbon monoxide (DLCO) ≤ 65% of expected Confirmed by pulmonary tests. d.&#xD;
             Diabetes mellitus with symptomatic end-organ damage (e.g., retinopathy, nephropathy,&#xD;
             neuropathy, vasculopathy) e. Autoimmune inflammatory conditions (e.g., rheumatoid&#xD;
             arthritis, systemic lupus erythematous, inflammatory bowel disease, or similar)&#xD;
             requiring chronic disease modifying therapy (e.g., etanercept, adalimumab, infliximab,&#xD;
             rituximab, methotrexate, or similar) f. Class III obesity defined as a Body Mass Index&#xD;
             (BMI) &gt; 40 kg/m2 g. Renal impairment defined as serum creatinine &gt; 1.3 mg/dL (&gt; 115&#xD;
             µmol/L) or creatinine clearance &lt;70 ml/min h. Clinically significant cognitive&#xD;
             impairment defined as requiring medical therapy and/or assistance with activities of&#xD;
             daily living&#xD;
&#xD;
          3. 20% blasts in bone marrow&#xD;
&#xD;
          4. Peripheral white blood cell (WBC) count 30,000/µL For cyto-reduction, hydroxyurea is&#xD;
             allowed during screening and up to Cycle 1, Days 1-14, to reduce WBC count to &lt; 30,000&#xD;
             µL prior to Day 1. After Cycle 1, Day 14, hydroxyurea is prohibited.&#xD;
&#xD;
          5. ECOG performance status ≤ 2&#xD;
&#xD;
          6. Adequate organ function as evidenced by the following laboratory findings:&#xD;
&#xD;
               1. Total bilirubin ≤ 2 × upper limit of normal (ULN) or &lt; 3 x ULN for patients with&#xD;
                  Gilbert-Meulengracht Syndrome&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN&#xD;
&#xD;
          7. Serum creatinine ≤ 1.5 × ULN according to institutional standards or creatinine&#xD;
             clearance ≥ 50 mL/min&#xD;
&#xD;
          8. QT-interval corrected according to Fridericia's formula (QTcF) ≤ 450 ms on&#xD;
             electrocardiogram (ECG) at Screening&#xD;
&#xD;
          9. Male patient who is surgically sterile, or male patient who is willing to agree to&#xD;
             remain completely abstinent (refrain from heterosexual intercourse) or who use barrier&#xD;
             contraceptive measures and agree to refrain from donating sperm during the entire&#xD;
             study treatment period and for 3 months after the last administration of study drug&#xD;
&#xD;
         10. Female patient who is of childbearing potential willing to use adequate contraceptive&#xD;
             measures while participating on study, OR willing to completely abstain from&#xD;
             heterosexual intercourse during the entire study treatment period&#xD;
&#xD;
         11. Female patient who is of childbearing potential must have a negative serum pregnancy&#xD;
             test result within 3 weeks prior to starting study drugs.&#xD;
&#xD;
         12. Willing to provide voluntary written informed consent before performance of any study&#xD;
             related procedure not part of normal medical care&#xD;
&#xD;
         13. Willing and able to understand the nature of this study and to comply with the study&#xD;
             and follow-up procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Able to receive intensive induction chemotherapy&#xD;
&#xD;
          2. AML-associated inv(16)/t(16;16)/del(16q), t(15;17) (i.e. promyelocytic leukemia)&#xD;
             with/without secondary aberrations; t(8;21) lacking del (9q) or complex karyotypes&#xD;
&#xD;
          3. Presence of an active malignant disease within the last 12 months, with the exception&#xD;
             of adequately treated cervical cancer in-situ, non-melanoma skin cancer and&#xD;
             superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1&#xD;
             [tumor invades lamina propria]). Other malignancies may be considered after&#xD;
             consultation with the Medical Monitor&#xD;
&#xD;
          4. Life-threatening illnesses other than AML, uncontrolled medical conditions or organ&#xD;
             system dysfunction that, in the Investigator's opinion, could compromise the patient's&#xD;
             safety or put the study outcomes at risk&#xD;
&#xD;
          5. Uncontrolled arrhythmias; any Class 3-4 cardiac diseases as defined by the New York&#xD;
             Heart Association (NYHA) functional classification&#xD;
&#xD;
          6. Evidence of AML central nervous system (CNS) involvement&#xD;
&#xD;
          7. Previous chemotherapy for AML except for the following, which are allowed:&#xD;
&#xD;
               1. Hydroxyurea for cytoreduction&#xD;
&#xD;
               2. One course of hypomethylating agent therapy (i.e.; up to 7 doses of azacitidine&#xD;
                  or 3-5 days of decitabine) within 30 days prior to enrollment (Day 1)&#xD;
&#xD;
          8. Use of experimental drugs ≤ 30 days prior to screening&#xD;
&#xD;
          9. Received prior HDAC inhibitor therapy&#xD;
&#xD;
         10. Received prior treatment with a hypomethylating agent, except as allowed in Exclusion&#xD;
             Criterion 7.b&#xD;
&#xD;
         11. Known hypersensitivity to any components of pracinostat, azacitidine, or mannitol&#xD;
&#xD;
         12. History of human immunodeficiency virus (HIV) or an active and uncontrolled infection&#xD;
             with hepatitis C virus (HCV) or hepatitis B virus (HBV)&#xD;
&#xD;
         13. Gastrointestinal (GI) tract disease that causes an inability to take oral medication,&#xD;
             malabsorption syndrome, or a requirement for IV alimentation; prior surgical&#xD;
             procedures affecting absorption; or uncontrolled inflammatory GI disease (e.g.,&#xD;
             Crohn's disease, ulcerative colitis)&#xD;
&#xD;
         14. Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a&#xD;
             physical examination or clinical laboratory test result that would cause reasonable&#xD;
             suspicion of a disease or condition, that contraindicates the use of pracinostat&#xD;
             and/or AZA, that may increase the risk associated with study participation, that may&#xD;
             affect the interpretation of the results, or that would make the patient inappropriate&#xD;
             for this study&#xD;
&#xD;
         15. Breast-feeding woman&#xD;
&#xD;
         16. current smokers(use of patches, chewing gums and vaping nicotine conaining fluids is&#xD;
             permitted). Patients who stopped smoking at least 8 day prior to first pracinostat&#xD;
             dosing can be enrolled, provided they refrain from smoking during the whole study&#xD;
&#xD;
         17. prohibited concomitant medications&#xD;
&#xD;
         18. uncontrolled infections&#xD;
&#xD;
         19. receive more than 1 prior cycle of HMA or bone marrow transplant for any prior&#xD;
             hematological disorder antecedent to AML&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Garcia-Manero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MD Anderson</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo clinic hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, East Valley Cancer Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona cancer center-north campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10666 N.Torrey Pines-Scripps Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint alphonsus Regional medical center-cancer care center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Chicago</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitz of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, St. Matthews Campus</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontchartrain Cancer Center (Research Location)</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rcca Md Llc</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial medical center-university campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center of Medical Research</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Research</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>100 Mercy Way</name>
      <address>
        <city>Joplin</city>
        <state>Montana</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center-2400 Pratt Street</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Oncology &amp; Hematology</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma cancer specialist and research institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHS Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North texas Health Care sytem,Dallas VA Medical Center div. Hematology Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emily Couric Clinical cancer center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Reeve Chauncey</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital italiano de Buenos Aires</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Especializado Alexander Fleming</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>hospital Italiano la Plata</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AXI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico SA Paraguay 40, 3P</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanatorio Allende</name>
      <address>
        <city>Córdoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H ospi tal Privado de Cordoba</name>
      <address>
        <city>Córdoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine coast university hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Northern hospital Pharmacy Department, Ground Floor</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Health, University Hospital Geelong</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital, Clinical Trial Pharmacy</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Müllner Hauptstrabe 48</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liga Paranaense de Com bate ao Cancer - Hospital Erasto Gaertner</name>
      <address>
        <city>Curitiba</city>
        <state>Paranà</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ce ntro de Pesquisas Hospital Amara l Ca rvalh o</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clinica do Hospital Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>0827-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <zip>1478-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Casa de Belo Horizonte -Serviyo de Oncologia Clinica</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30.150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Oncologicas - CEPON</name>
      <address>
        <city>Florianópolis</city>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de ClÃ-nicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Nacional de Cancer Jose de Alencar Gomes da Silva-INCA</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC - Centro de Estudos e Pesquisas de Hematologia e Oncologia</name>
      <address>
        <city>Santo André</city>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de Sao Jose do Rio Preto</name>
      <address>
        <city>São José Do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Fakultni nemocnice Hradec Kralove,</name>
      <address>
        <city>Hradec Králové</city>
        <zip>5oo 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomuc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice</name>
      <address>
        <city>Praha 2</city>
        <zip>I28 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Fakultni nemocnice Kralovske Vinohrady,</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady,</name>
      <address>
        <city>Praha</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie-Site Sud-Service d'Hematologie</name>
      <address>
        <city>Amiens</city>
        <zip>800054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Hopital privé du Confluent SAS</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice, Archet 1 Hospital-Hematology department</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital saints Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haut-Leveque-Service d'hématologie clinique et de thérapie cellular</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen Cedex 1</city>
        <zip>76028</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Marien Amberg</name>
      <address>
        <city>Amberg</city>
        <state>Bayern</state>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Herne-Universitätsklinikum der Ruhr-Universität Bochum</name>
      <address>
        <city>Herne</city>
        <state>North Rhine-westphalia</state>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité-Universitätsmedizin - 1. Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches krankenhaus kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>university of Pécs</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Egyetem I. Belgy6gyaszati Klinika</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Istvan &amp; St. Laszlo Hospital, Deapartment of Hematology and Stem Cell Transplantation</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Clinical Center</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz, Dep. Of Haematology</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg megyei Korhazak es Egyetemi Oktatokorhaz â€&quot; Josa Andras Oktatokorhaz, Hematologiai Osztaly</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>II-1065</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele-U.O. Ematologia e TMO</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale la Maddalena, UO Oncoematologia e TMO</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Consorziale di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Università Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliere Antonio Cardarelli,</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS policlinico San Matteo Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV-Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje university Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil medical center, div hematology</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, Div.Hematology/Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>0080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumsung medical center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary Hospital, div hemato-oncology</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Examen Sp. Z o.o.,</name>
      <address>
        <city>Poznań</city>
        <zip>60-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyc:my Szpi tal im. dra Alfreda Sokolowskiego</name>
      <address>
        <city>Wałbrzych</city>
        <zip>58-309</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Wielospecjalistyczne Centrum onkologii I traumatologii</name>
      <address>
        <city>Łódź</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Filantropia</name>
      <address>
        <city>Craiova</city>
        <state>Jud.dolj</state>
        <zip>200143</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>clinical hospital Coltea Bld</name>
      <address>
        <city>Bucuresti</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Bucuresti</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncological Institute &quot;Ion Chiricuta&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>institutu Regional de Oncologie Iasi</name>
      <address>
        <city>Iaşi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català D'Oncologia (ICO)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <state>Extremadura</state>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp.Universitario A Coruña-Hospital Teresa Herrera</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Isla Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univers itario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Uni vcrsitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>46013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico de La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology, Changhwa Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospita</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>koo-Foundation Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital (Wonford site)</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX25DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Foundation trust</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire NHS Trust</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 20, 2021</submitted>
    <returned>September 15, 2021</returned>
    <submitted>September 28, 2021</submitted>
    <returned>October 27, 2021</returned>
    <submitted>November 4, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

